Dr. Reddy’s Laboratories has received a Pre-Approval Inspection (PAI) letter from the US Food and Drug Administration (USFDA) for its biologics facility located in Hyderabad, India. This letter indicates that the USFDA has completed its inspection of the facility and has found it to be compliant with the required standards.<\/p>\n
The USFDA conducts pre-approval inspections to ensure that manufacturing facilities meet the necessary regulatory requirements before approving a new drug application. The inspection is a critical step in the approval process, and receiving a PAI letter is a significant milestone for Dr. Reddy’s Laboratories.<\/p>\n
The Hyderabad biologics facility is a state-of-the-art manufacturing site that produces a range of biological products, including monoclonal antibodies and other biologic drugs. The facility has been designed to meet the highest international standards of quality and safety, and the USFDA’s pre-approval inspection is a testament to the facility’s compliance with these standards.<\/p>\n
The receipt of the PAI letter is a positive development for Dr. Reddy’s Laboratories, as it brings the company one step closer to receiving approval for its biologic products in the US market. The company has been expanding its presence in the biologics market in recent years, and this development is expected to further strengthen its position in this segment.<\/p>\n
The USFDA’s inspection process is rigorous and thorough, and the fact that Dr. Reddy’s Laboratories has received a PAI letter suggests that the facility has met the required standards. The company will now await the final approval from the USFDA, which is expected to be granted in the coming months.<\/p>\n
The approval of Dr. Reddy’s biologics facility by the USFDA is significant not only for the company but also for the Indian pharmaceutical industry as a whole. It demonstrates the capability of Indian companies to meet international standards of quality and safety, and it is expected to boost the confidence of global regulatory agencies in the Indian pharmaceutical industry.<\/p>\n
In conclusion, the receipt of the PAI letter by Dr. Reddy’s Laboratories is a significant development that brings the company closer to receiving approval for its biologic products in the US market. The company’s biologics facility in Hyderabad has been found to be compliant with the required standards, and the final approval from the USFDA is expected to be granted in the coming months. This development is expected to further strengthen Dr. Reddy’s position in the biologics market and boost the confidence of global regulatory agencies in the Indian pharmaceutical industry.<\/p>\n","protected":false},"excerpt":{"rendered":"
Dr. Reddy’s Laboratories has received a Pre-Approval Inspection (PAI) letter from the US Food and Drug Administration (USFDA) for its biologics facility located in Hyderabad, India. This letter indicates that the USFDA has completed its inspection of the facility and has found it to be compliant with the required standards. The USFDA conducts pre-approval inspections […]<\/p>\n","protected":false},"author":1,"featured_media":88041,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[15],"tags":[],"class_list":["post-89794","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dr-reddys"],"jetpack_featured_media_url":"https:\/\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89847,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/24\/us-fda-concludes-inspection-at-zydus-ankleshwar-facility-with-three-noted-observations\/","url_meta":{"origin":89794,"position":0},"title":"US FDA Concludes Inspection at Zydus’ Ankleshwar Facility with Three Noted Observations.","author":"Team Small News","date":"January 24, 2026","format":false,"excerpt":"The US Food and Drug Administration (USFDA) has completed an inspection at Zydus Cadila's manufacturing facility in Ankleshwar, Gujarat, with three observations. The inspection was conducted from February 13 to February 17, 2023. Although the company has not provided detailed information about the observations, it has stated that they are\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89802,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/15\/dr-reddys-introduces-generic-version-of-antihistamine-eye-drops-to-the-us-market\/","url_meta":{"origin":89794,"position":1},"title":"Dr Reddy’s introduces generic version of antihistamine eye drops to the US market","author":"Team Small News","date":"January 15, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories has launched an over-the-counter (OTC) eye drop solution, Olopatadine Hydrochloride Ophthalmic Solution, in the US market. The solution is a generic equivalent of Extra Strength Pataday Once-Daily Relief, which is used to provide temporary relief from itchy eyes caused by pollen, ragweed, grass, animal hair, and dander.\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89836,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/22\/dr-reddys-relies-on-biosimilars-and-weight-loss-medication-launches-to-compensate-for-declining-us-dominance-of-revlimid\/","url_meta":{"origin":89794,"position":2},"title":"Dr Reddy’s relies on biosimilars and weight-loss medication launches to compensate for declining US dominance of Revlimid.","author":"Team Small News","date":"January 22, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories, a leading Indian pharmaceutical company, is shifting its focus towards biosimilars and a new weight-loss drug to drive growth as its exclusivity for the generic version of Revlimid in the US market is set to expire. Revlimid, a blood cancer treatment, has been a significant contributor to\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89748,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/04\/delhi-high-court-bars-dr-reddys-from-producing-venusia-sunscreens-bearing-the-sun-logo\/","url_meta":{"origin":89794,"position":3},"title":"Delhi High Court bars Dr Reddy’s from producing VENUSIA sunscreens bearing the SUN logo.","author":"Team Small News","date":"January 4, 2026","format":false,"excerpt":"The Delhi High Court has issued an interim order restraining Dr. Reddy's Laboratories from manufacturing and selling its VENUSIA sunscreens with a label that includes the word \"SUN\". The court's decision comes in response to a lawsuit filed by Glenmark Pharmaceuticals, which claims that Dr. Reddy's is infringing on its\u2026","rel":"","context":"In "Glenmark"","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89742,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/03\/biotech-healthcare-group-names-pankaj-phatak-as-its-new-vice-president-of-human-resources-as-reported-by-ethrworld\/","url_meta":{"origin":89794,"position":4},"title":"Biotech Healthcare Group names Pankaj Phatak as its new Vice President of Human Resources, as reported by ETHRWorld.","author":"Team Small News","date":"January 3, 2026","format":false,"excerpt":"Pankaj Phatak has been appointed as the Vice President of Human Resources at Biotech Healthcare Group. In this role, he will be responsible for driving the HR function globally. Phatak expressed his excitement about the new opportunity, stating that he looks forward to advancing a purpose-driven global people agenda and\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89763,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/07\/dr-reddys-introduces-hevaxin-indias-inaugural-hepatitis-e-vaccine-approved-by-the-dcgi-specifically-designed-for-adult-use\/","url_meta":{"origin":89794,"position":5},"title":"Dr. Reddy’s introduces Hevaxin, India’s inaugural Hepatitis E vaccine approved by the DCGI, specifically designed for adult use.","author":"Team Small News","date":"January 7, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories has launched Hevaxin, a novel recombinant vaccine for the prevention of Hepatitis E virus (HEV) infection in India. This vaccine is the only one approved by the Drug Controller General of India (DCGI) for active immunization against HEV infection in adults aged 18 to 65 years. Clinical\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89794","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89794"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89794\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media\/88041"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89794"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89794"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}